RE: Opportunity25 Jul 2024 12:58
I wonder whether the companies Conjugate will be tested at the new AZ facility in Singapore It is developed as an alternative to Antibody conjugates faster more efficient and far less costly An extremely valuable tool Clearly acquisitive AZ are not going to miss the boat. From their half yearly report today:
In May 2024, AstraZeneca announced its intention to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody. The planned greenfield facility, supported by the Singapore Economic Development Board, will be AstraZeneca's first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale. Manufacturing of ADCs is a multi-step process that comprises antibody production, synthesis of chemotherapy drug and linker, conjugation of drug-linker to the antibody, and filling of the completed ADC substance.
Just a thought as its best we don't leave stones unturned!